

CODIGO : 170197
NOMBRE PACIENTE : SARA VICTORIA MOSQUERA VALENCIA **SEXO :** FEMENINO
FECHA DE NACIMIENTO : 24/08/2025 **REGISTRO CIVIL :** 1,107,871,781
NOMBRE RESPONSABLE : ANGIE CAROLINA VALENCIA GOMEZ
DOC.IDENTIDAD DE LA MADRE : 1,059,915,837
FECHA TOMA DE MUESTRA : 13/09/2025
FECHA DE IMPRESION : 07/10/2025



TAMIZAJE NEONATAL

ANALISIS MUESTRA DE SANGRE

	RESULTADO	VALORES DE REFERENCIA	INTERPRETACION
Hipotiroidismo congénito	2.22	VN: < 10 uU/ml	Normal
Deficiencia de G6PDH	6.70	VN : > 2.6 U/gHb	Normal
Fenilcetonuria (PKU)	0.70	VN : < 2.1 mg/dL	Normal
<i>TÉCNICA: Fluoroimmunoensayo (Delfia).</i>			<i>Procesado en Colombia por PREGEN.</i>
Hemoglobinopatías	FA	Ausencia de hemoglobinas anormales	Normal
<i>TÉCNICA: Cromatografía Líquida de Alto Rendimiento (HPLC).</i>			<i>Procesado en Colombia por PREGEN.</i>

TAMIZAJE AMPLIADO

ESPECTROMETRIA DE MASAS EN TANDEM

Procesado en Tennessee Department of Health.

DESORDENES DE AMINOÁCIDOS

Citrulina, Metionina, Leucina, Isoleucina, Valina, Fenilalanina, Tirosina.
 Ausencia de metabolitos anormales Normal

DESORDENES DE LA OXIDACIÓN DE ÁCIDOS GRASOS

C16, C18, C18:1, C16OH, C18:1OH, C8, C10:1, C5, C5DC, C4, C14, C14:1
 Ausencia de metabolitos anormales Normal

ACIDEMIAS ORGÁNICAS

C5OH, C5DC, C5, C3, C5:1
 Ausencia de metabolitos anormales Normal

RESULTADOS NORMALES

Recuerde que estas son pruebas de tamizaje que solo indican la probabilidad de que el recién nacido tenga una de las enfermedades estudiadas por el programa y pueden requerir pruebas adicionales para la confirmación de algún diagnóstico. La sensibilidad de estas pruebas se reduce a medida que aumenta la edad del paciente, por esto es conveniente realizarlas dentro del primer mes de nacido.

REVISADO : EDUVILIA JOHANA GOMEZ
 Bacteriologa
 Reg. 40.936.003

FECHA : 07/10/2025



Department of
Health

**TENNESSEE DEPARTMENT of HEALTH
LABORATORY SERVICES**

Kara Levinson, PhD, MPH, D(ABMM), Director
630 Hart Lane Nashville, TN 37243-0801
615-262-6300



**NEWBORN SCREENING REPORT
FIRST SPECIMEN**

Date: 9/26/2025

TDH Lab Number: 20252682289

Infant: **MOSQUERA VALENCIA, SARA VICTORIA**
Birth Date: 8/24/2025 @ 03:45
Collect Date: 9/13/2025 @ 09:44
Date Recvd: 9/25/2025 @ 0700
Sex: Female
*Feeding:
Multiple Birth: Single

Mother: VALENCIA, ANGIE CAROLINA
Address: NO INFO GIVEN
Phone: NP
Race: White
SCN: TN0000177565
Gestage: 40.0

Medical Record:
*Transfused: No
Date Transf.:
County: SOUTH AMERICA
Birth Weight: 3660
Hospital: PREGEN
Provider: PREGEN

NEWBORN SCREENING RESULTS

*Disorder/Profile	Result	Remarks	Normal Values
Galactosemia (GAL)	Within Normal Limits	Normal	GAL < 13 mg/dL GALT >= 3.48 U/dL
Hemoglobinopathies (HGB)	FA	No Hemoglobinopathies Observed	FA, AF for Older Infants
Biotinidase Deficiency (BIO)	Within Normal Limits	Normal	>= 44.64 U/dL
Congenital Adrenal Hyperplasia (CAH)	Within Normal Limits	Normal	< 37 ng/mL
Amino Acid Profile (AA)	Within Normal Limits	Normal	Within Normal Limits
Organic Acid Profile (OA)	Within Normal Limits	Normal	Within Normal Limits
Fatty Acid Profile (FA)	Within Normal Limits	Normal	Within Normal Limits
Cystic Fibrosis (CF)	Within Normal Limits	Normal	< 54 ng/mL
X-linked Adrenoleukodystrophy (XALD)	Within Normal Limits	Normal	Within Normal Limits

*See website for additional information. https://www.tn.gov/content/dam/tn/health/program-areas/lab/nbs/NBS_Disorder_List_and_Mailer_Comments.pdf

The purpose of the Tennessee Department of Health Newborn Screening program is to identify infants at increased risk for a variety of disorders. This is a screening test and the results can be affected by different factors. The possibility of a false negative or a false positive result must always be considered when screening newborns for disorders. Therefore, newborn screening tests results are insufficient on which to base diagnosis or treatment. The test may need to be repeated and the diagnosis confirmed or ruled out by additional specialized studies.

CCHD Screen on NP @ NP CCHD Result: NP Referred to Cardiology: NP Reason if not done: NP NP = Not Provided


HEARING SCREENING: Method used - Not Performed. Left Ear. Not Performed. Right Ear. Not Performed. Risk Factor. None. Performed: .

The Hearing and Critical Congenital Heart Disease (CCHD) Screening was submitted on the Newborn Screening form by a medical provider. The Tennessee State Department of Health Laboratory Services did not conduct the screens. Questions should be referred to the Newborn Screening Program P(615)532-8462 / F(615)532-8555 or the hospital performing the test.

LABORATORIO PREGEN
 Carrera 15a No 106-42
 BOGOTA

Batch 1919, Rack A, Plate 1, Well H08, 170197
 [997012C155F4D19F] Sep 24, 2025 14:00:08 Pressure = 60 bar (59 to 61)

FA



PEAK	RT	REL RT	% CONC	AREA	COMMENT
1	0.407	F 0.48	1.7%	13864	
2	0.490	F 0.58	1.3%	11283	
3	0.705	F 0.83	16.3%	135834	Acetylated F peak
4	0.835	F 0.99	64.9%	542303	Consistent with F
5	0.988	F 1.17	0.8%	6838	
6	1.208	A 1.00	15.0%	125761	A peak
Total Area:				835883	

- Codes:
- 1) Wide A peak
 - 2) Area of A peak < 80%
 - 3) Peak area greater than expected
 - 4) Peak after A2
 - 5) Alc > 10%
 - 6) HbF or variant present
 - 7) Total sample area too small/big
 - 8) A2 is not within normal range